Nova Patents
AT321885T

Modulation of neuroendocrine differentiation by protein 25.1

Abstract

(57) The method for the tumor control including checking guidance of the neuroendocrine cell specialization in the drug screening assay method by use of the new IGFBP*rP1 interaction protein P25.1 as a target of summary intervention, the diagnostic authorizing method, and a cancer cell or cancer medical treatment is indicated. The present invention offers P25.1 cDNA arrangement, P25.1 polypeptide and its fragment, anti-P25.1 antibody, and anti-P25.1 antisense oligonucleotide again.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

27 members in 8 offices

This recordMember, by publication datePriority claim

Priority claims1

Priority claims
DocumentOfficeKindDate
16239399United States of AmericaP

Members27

Family members, oldest first
DocumentOfficeKind
CA2389372A1CanadaA1
CA2389575A1CanadaA1
WO0132925A1World Intellectual Property Organization (WIPO)A1
WO0133398A2World Intellectual Property Organization (WIPO)A2
AU1355501AAustraliaA
AU1355601AAustraliaA
EP1226279A1European Patent Office (EPO)A1
WO0132925A9World Intellectual Property Organization (WIPO)A9
WO0133398A8World Intellectual Property Organization (WIPO)A8
EP1252580A1European Patent Office (EPO)A1
JP2003513641AJapanA
EP1226279A4European Patent Office (EPO)A4
US6925468B1United States of AmericaB1
EP1226279B1European Patent Office (EPO)B1
AT321885TThis recordAustriaT
ATE321885T1AustriaT1
DE60027042D1GermanyD1
US7353196B1United States of AmericaB1
US7356541B1United States of AmericaB1
US7363264B1United States of AmericaB1
US7526487B1United States of AmericaB1
US7546304B1United States of AmericaB1
US7571171B1United States of AmericaB1
US7693844B1United States of AmericaB1
EP2339528A1European Patent Office (EPO)A1
EP2341480A1European Patent Office (EPO)A1
CA2389372CCanadaC